• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SUMOylation 对 miR-34b/c 靶向基因表达谱的调控。

Regulation of miR-34b/c-targeted gene expression program by SUMOylation.

机构信息

Department of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

出版信息

Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.

DOI:10.1093/nar/gky484
PMID:29893976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6101486/
Abstract

The miR-34 family of microRNAs suppresses the expression of proteins involved in pluripotency and oncogenesis. miR-34 expression is frequently reduced in cancers; however, the regulation of their expression is not well understood. We used genome-wide miRNA profiling and mechanistic analysis to show that SUMOylation regulates miR-34b/c expression, which impacts the expression of c-Myc and other tested miR-34 targets. We used site-directed mutagenesis and other methods to show that protein kinase B (also known as Akt) phosphorylation of FOXO3a plays an important role in SUMOylation-dependent expression of miR-34b/c. This study reveals how the miR-34-targeted gene expression program is regulated by SUMOylation and shows that SUMOylation need not regulate target proteins through direct modification, but instead can act through the expression of their targeting miRNAs.

摘要

miR-34 微 RNA 家族抑制多能性和致癌基因相关蛋白的表达。miR-34 的表达在癌症中经常减少;然而,它们的表达调控还不是很清楚。我们使用全基因组 miRNA 分析和机制分析表明,SUMO 化调节 miR-34b/c 的表达,这会影响 c-Myc 和其他测试的 miR-34 靶基因的表达。我们使用定点突变和其他方法表明,蛋白激酶 B(也称为 Akt)对 FOXO3a 的磷酸化在 SUMO 化依赖的 miR-34b/c 表达中起着重要作用。这项研究揭示了 miR-34 靶向基因表达程序如何被 SUMO 化调控,并表明 SUMO 化不必通过直接修饰来调节靶蛋白,而是可以通过表达它们的靶向 miRNA 来发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/613c2908a715/gky484fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/9c16fb7accfc/gky484fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/8db708f9daa5/gky484fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/9b84311c4b5a/gky484fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/4117d4695025/gky484fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/097647220a11/gky484fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/4ee4a8cc4ae9/gky484fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/613c2908a715/gky484fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/9c16fb7accfc/gky484fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/8db708f9daa5/gky484fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/9b84311c4b5a/gky484fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/4117d4695025/gky484fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/097647220a11/gky484fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/4ee4a8cc4ae9/gky484fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f376/6101486/613c2908a715/gky484fig7.jpg

相似文献

1
Regulation of miR-34b/c-targeted gene expression program by SUMOylation.SUMOylation 对 miR-34b/c 靶向基因表达谱的调控。
Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.
2
The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer.miR-21-FOXO3a-miR-34b/c信号通路在乳腺癌中的调控及功能
Int J Mol Sci. 2015 Jan 30;16(2):3148-62. doi: 10.3390/ijms16023148.
3
miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.微小RNA-22靶向14-3-3ζ以抑制肝细胞癌转移,其表达下调预示着预后不良。
Oncotarget. 2016 Dec 6;7(49):80751-80764. doi: 10.18632/oncotarget.13037.
4
miR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling.微小RNA-194通过降低PI3K-Akt-FoxO3a信号传导来调控AGK并抑制口腔鳞状细胞癌的细胞增殖。
Biomed Pharmacother. 2015 Apr;71:53-7. doi: 10.1016/j.biopha.2015.02.011. Epub 2015 Feb 26.
5
MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway.微小RNA-608通过AKT/FOXO3a信号通路抑制膀胱癌的增殖。
Mol Cancer. 2017 May 26;16(1):96. doi: 10.1186/s12943-017-0664-1.
6
Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.甲基化的鞣花酸A,一种源自修饰鞣花单宁的代谢产物,通过靶向miR-21抑制DU145人前列腺癌细胞的细胞活力。
Food Chem Toxicol. 2016 Nov;97:375-384. doi: 10.1016/j.fct.2016.10.005. Epub 2016 Oct 8.
7
Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis.JNK 和 FOXO3 上调 miR-34b/c 可预防肝纤维化。
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10). doi: 10.1073/pnas.2025242118.
8
The mechanisms involved in miR-9 regulated apoptosis in cervical cancer by targeting FOXO3.miR-9 通过靶向 FOXO3 调控宫颈癌细胞凋亡的机制研究。
Biomed Pharmacother. 2018 Jun;102:626-632. doi: 10.1016/j.biopha.2018.03.019. Epub 2018 Apr 5.
9
Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.对微小RNA调控的蛋白质相互作用网络的综合分析揭示了微小RNA - 149通过靶向AKT - mTOR途径在人类肝细胞癌中的肿瘤抑制作用。
Mol Cancer. 2014 Nov 26;13:253. doi: 10.1186/1476-4598-13-253.
10
miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A.miR-1307 通过靶向 FOXO3A 促进前列腺癌的增殖。
Biomed Pharmacother. 2017 Apr;88:430-435. doi: 10.1016/j.biopha.2016.11.120. Epub 2017 Jan 22.

引用本文的文献

1
The SUMO Family: Mechanisms and Implications in Thyroid Cancer Pathogenesis and Therapy.SUMO家族:在甲状腺癌发病机制与治疗中的作用机制及意义
Biomedicines. 2024 Oct 21;12(10):2408. doi: 10.3390/biomedicines12102408.
2
MiRNA Dysregulation in Brain Injury: An Study to Clarify the Role of a MiRNA Set.脑损伤中的微小RNA失调:一项阐明一组微小RNA作用的研究
Curr Neuropharmacol. 2025;23(2):209-231. doi: 10.2174/1570159X22666240808124427.
3
Regulation of Enhancers by SUMOylation Through TFAP2C Binding and Recruitment of HDAC Complex to the Chromatin.

本文引用的文献

1
Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal.SUMO 激活酶在癌症干细胞维持和自我更新中的作用。
Nat Commun. 2016 Jul 28;7:12326. doi: 10.1038/ncomms12326.
2
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.维奈托克:抑制Bcl-2用于治疗慢性淋巴细胞白血病。
Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.
3
Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.帕博西尼:CDK4/6抑制在雌激素受体阳性乳腺癌治疗中的应用
通过TFAP2C结合以及组蛋白去乙酰化酶复合物募集到染色质上的SUMO化修饰对增强子进行调控。
Res Sq. 2024 Apr 2:rs.3.rs-4201913. doi: 10.21203/rs.3.rs-4201913/v1.
4
Identification of ITPR1 gene as a novel target for hsa-miR-34b-5p in non-obstructive azoospermia: a Ca/apoptosis pathway cross-talk.鉴定 ITPR1 基因为非阻塞性无精子症中 hsa-miR-34b-5p 的新靶点:Ca/凋亡途径的串扰。
Sci Rep. 2023 Dec 10;13(1):21873. doi: 10.1038/s41598-023-49155-5.
5
Critical Non-Covalent Binding Intermediate for an Allosteric Covalent Inhibitor of SUMO E1.SUMO E1变构共价抑制剂的关键非共价结合中间体
J Phys Chem Lett. 2023 Mar 23;14(11):2792-2799. doi: 10.1021/acs.jpclett.3c00253. Epub 2023 Mar 10.
6
SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.泛素化抑制增强多发性骨髓瘤对来那度胺的敏感性。
Cancer Gene Ther. 2023 Apr;30(4):567-574. doi: 10.1038/s41417-022-00450-9. Epub 2022 Mar 25.
7
SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.SUMOylation 抑制增强多发性骨髓瘤对地塞米松的敏感性。
J Exp Clin Cancer Res. 2022 Jan 4;41(1):8. doi: 10.1186/s13046-021-02226-9.
8
miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy.微小RNA在癌症免疫反应调控中的作用:微小RNA对癌症免疫治疗的影响
Cancers (Basel). 2021 Dec 6;13(23):6145. doi: 10.3390/cancers13236145.
9
Mesenchymal Stem Cell-derived Extracellular Vesicles Transmitting MicroRNA-34a-5p Suppress Tumorigenesis of Colorectal Cancer Through c-MYC/DNMT3a/PTEN Axis.间充质干细胞来源的细胞外囊泡传递 microRNA-34a-5p 通过 c-MYC/DNMT3a/PTEN 轴抑制结直肠癌的发生。
Mol Neurobiol. 2022 Jan;59(1):47-60. doi: 10.1007/s12035-021-02431-9. Epub 2021 Oct 8.
10
SUMOylation of E2F1 Regulates Expression of EZH2.SUMOylation 调控 E2F1 对 EZH2 的表达。
Cancer Res. 2020 Oct 1;80(19):4212-4223. doi: 10.1158/0008-5472.CAN-20-1259. Epub 2020 Aug 14.
Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528.
4
Targeting c-Met in Cancer by MicroRNAs: Potential Therapeutic Applications in Hepatocellular Carcinoma.微小RNA靶向癌症中的c-Met:在肝细胞癌中的潜在治疗应用
Drug Dev Res. 2015 Nov;76(7):357-67. doi: 10.1002/ddr.21274. Epub 2015 Sep 12.
5
c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.c-Myc以一种依赖于SUMO化的方式靶向蛋白酶体进行降解,这一过程受PIAS1、SENP7和RNF4调控。
Cell Cycle. 2015;14(12):1859-72. doi: 10.1080/15384101.2015.1040965.
6
SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.Akt的SUMO修饰通过Ubc9和SUMO1的Akt磷酸化调节整体SUMO化和底物SUMO化特异性。
Oncogene. 2016 Feb 4;35(5):595-607. doi: 10.1038/onc.2015.115. Epub 2015 Apr 13.
7
Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.小泛素样修饰物(SUMO)途径功能丧失对癌细胞和肿瘤增殖的特征分析。
PLoS One. 2015 Apr 10;10(4):e0123882. doi: 10.1371/journal.pone.0123882. eCollection 2015.
8
The role of YY1 in oncogenesis and its potential as a drug target in cancer therapies.YY1在肿瘤发生中的作用及其作为癌症治疗药物靶点的潜力。
Curr Cancer Drug Targets. 2015;15(2):145-57. doi: 10.2174/1568009615666150131124200.
9
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.由Ras/Raf信号通路驱动的肿瘤发生需要SUMO E2连接酶Ubc9。
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1724-33. doi: 10.1073/pnas.1415569112. Epub 2015 Mar 24.
10
COXPRESdb in 2015: coexpression database for animal species by DNA-microarray and RNAseq-based expression data with multiple quality assessment systems.2015年的COXPRESdb:基于DNA微阵列和RNA测序的表达数据、带有多个质量评估系统的动物物种共表达数据库。
Nucleic Acids Res. 2015 Jan;43(Database issue):D82-6. doi: 10.1093/nar/gku1163. Epub 2014 Nov 11.